Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference
Onconova Therapeutics (NASDAQ: ONTX) has announced that Steven Fruchtman, M.D., President & CEO, will present a virtual company update at the 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be on-demand starting February 19. The company focuses on developing novel cancer treatments, including the multi-kinase inhibitor ON 123300, currently in Phase 1 trials in China, and rigosertib, which is also under investigation for COVID-19. For more details, visit www.onconova.com.
- None.
- None.
NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present a virtual Company update at the 2021 BIO CEO & Investor Digital Conference being held February 16-18, 2021. Avi Oler, Senior VP, Corporate Development, will be available for 1x1 meetings scheduled through the Bio Partnering system.
Dr. Fruchtman’s presentation will be available on demand during the conference, and a replay will be available here beginning February 19.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion Phase 1 trial is planned in the U.S. to commence in the first half of 2021. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, Onconova has commenced preclinical work investigating rigosertib in COVID-19. For more information, please visit www.onconova.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including [patient enrollment timelines and] indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Contact information
Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/
Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
FAQ
When will Onconova Therapeutics present at the 2021 BIO CEO & Investor Digital Conference?
Who will present at the Onconova Therapeutics conference?
What is Onconova's multi-kinase inhibitor ON 123300?
Is ONTX conducting any studies related to COVID-19?
Where can I find more information about Onconova Therapeutics?
